ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interferons"

  • Abstract Number: 2900 • 2019 ACR/ARP Annual Meeting

    Interferon Signature Predicts Response to Tofacitinib in Haploinsufficiency of A20

    Sarah Blackstone1, Daniella Schwartz 1, Natalia Sampaio Moura 1, Deborah Stone 1, Meryl Waldman 1, Patrycja Hoffmann 1, Anne Jones 1, Tina Romeo 1, Karyl Barron 1, Joshua Milner 1, Daniel Kastner 1 and Amanda Ombrello 1, 1National Institutes of Health, Bethesda, MD

    Background/Purpose: The protein A20, encoded by TNFAIP3, represses signaling upstream of the inflammatory transcription factor nuclear factor (NF)-kB by regulating ubiquitination. Heterozygous loss-of-function mutations in…
  • Abstract Number: 1026 • 2019 ACR/ARP Annual Meeting

    Interferon Lambda Promotes Age-Associated B Cells

    Jennifer Barnas1, Nida Meednu 1, Andrew McDavid 1, Jennifer Albrecht 1, Christopher Richardson 1, R. John Looney 2 and Jennifer Anolik 1, 1University of Rochester Medical Center, Rochester, NY, 2University of Rochester Medical Center, Rochester

    Background/Purpose: Age-associated B cells (ABC), defined as CD11c+ T-bet+ or CD11c+CD21-, represent a subset of B lymphocytes that are increased in systemic lupus erythematosus (SLE)…
  • Abstract Number: 2909 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of the Selective Interleukin-1 Receptor Associated Kinase 4 Inhibitor, PF-06650833, in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

    Spencer I Danto1, Negin Shojaee 1, Ravi Shankar P Singh 1, Zorayr Manukyan 2, Jessica Mancuso 1, Elena Peeva 1, Michael Vincent 1 and Jean Beebe 1, 1Pfizer Worldwide Research & Development, Immunology, and Inflammation Research Unit, Cambridge, MA, 2Pfizer Worldwide Research & Development, Immunology, and Inflammation Research Unit, ..

    Background/Purpose: Adaptive and innate immune pathways are involved in inflammation and pathogenesis of rheumatoid arthritis (RA). Toll-like receptor (TLR) stimulation activates the innate immune system,…
  • Abstract Number: 1296 • 2019 ACR/ARP Annual Meeting

    Increased MxA Protein Expression and Dendritic Cells in Spongiotic Dermatitis Differentiates Dermatomyositis from Eczema

    Majid Zeidi1, Kristen Chen 1, Basil Patel 2, Rachel Lim 3 and Victoria Werth 1, 1Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, 2Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, 3Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA, Philadelphia

    Background/Purpose: Dermatomyositis (DM) is conventionally characterized by interface dermatitis (ID) on skin histopathology. A subset of patients with clinically diagnosed DM have skin biopsies showing…
  • Abstract Number: 1455 • 2019 ACR/ARP Annual Meeting

    B and T Cell Immunologic Features Associated with Higher Disease Activity Score and Focus Score in Primary Sjögren Syndrome

    Alice Mai1, Yuriy Baglaenko 2, Dario Ferri 3, Kieran Manion 4, Dennisse Bonilla 5, Arthur Bookman 6 and Joan Wither 7, 1University of British Columbia Department of Rheumatology, Vancouver, Canada, 2Brigham Woman's Hospital, Boston, 3University Health Network, Toronto, ON, Canada, 4Krembil Research Institute, Toronto, ON, Canada, 5University Health Network, University of Toronto, Toronto, ON, Canada, 6University Health Network, Toronto, Canada, 7University Health Network, Krembil Research Institute, Toronto, ON, Canada

    Background/Purpose: Primary Sjögren syndrome (pSS) is a systemic autoimmune disease with an incompletely understood pathogenesis and heterogenous disease manifestations. Identifying cellular immune changes that may…
  • Abstract Number: 1762 • 2019 ACR/ARP Annual Meeting

    UV Light Induces Acute Type I Interferon Production in the Skin and Blood Which Is cGAS Dependent

    Sladjana Skopelja-Gardner1, Jie An 2, Xizhang Sun 2, Lena Tanaka 2, Joyce Tai 2, Payton Hermanson 2, Masaoki Kawasumi 2 and Keith Elkon 2, 1University of Washington, Seattle, WA, 2University of Washington, Seattle

    Background/Purpose: Interferon response genes (ISG) are strongly expressed in the skin of many patients with systemic lupus erythematosus (SLE). Since plasmacytoid dendritic cells (pDC) are…
  • Abstract Number: 1866 • 2019 ACR/ARP Annual Meeting

    Gene Expression Meta-Analysis Reveals Commonalities in Gene Activation and Enrichment of Immune Pathways and Cell Types in Dermatomyositis Target Tissues

    Jessica Neely1, Dmitry Rychkov 1, Manish Paranjpe 1, Michael Waterfield 2, Susan Kim 1 and Marina Sirota 2, 1University of California, San Francisco, San Francisco, CA, 2University of California, San Francisco, San Francisco

    Background/Purpose: Dermatomyositis (DM) is a complex immune-mediated disease resulting in muscle and skin inflammation.  Prior studies of gene expression in DM have revealed a type…
  • Abstract Number: 1869 • 2019 ACR/ARP Annual Meeting

    Myeloid Dendritic Cells (mDCs) Are Major Producers of Interferon-β in Dermatomyositis and Higher Numbers of mDCs Are Found in Hydroxychloroquine Nonresponders

    Kristen Chen1, Majid Zeidi 1, Maria Wysocka 2, Nithin Reddy 1, Arvin Jadoo 1, Muhammad Bashir 1, Sarah Ahmed 2, Basil Patel 2, Kevin Zhang 2, Barbara White 3 and Victoria Werth 1, 1Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, 2Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, 3Corbus Pharmaceuticals, Norwood, MA

    Background/Purpose: Dermatomyositis (DM) is an autoimmune disease affecting the skin, skeletal muscle, lungs, and/or other organs. While the pathogenesis remains poorly understood, it is thought…
  • Abstract Number: 1914 • 2019 ACR/ARP Annual Meeting

    Increased Risk of Progression to Lupus Nephritis for Lupus Patients with Elevated Interferon Signature

    Cristina Arriens1, Quratul Raja 2, Syed Ali Husain 2, Bessy George 2, Majid Abedi 3, Aviva Jacobs 4, Timothy Guyon 4, Hemani Wijesuriya 3, Teresa Aberle 5, Aikaterini Thanou 5, Stan Kamp 5, Susan R. Macwana 5, Eliza F. Chakravarty 1, Joan T. Merrill 6, Judith James 1, Robert Terbrueggen 4 and Joel Guthridge 1, 1Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3DxTerity Diagnostics Inc, Anaheim, CA, 4DxTerity Diagnostics Inc, Rancho Dominguez, CA, 5Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Okalahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: The interferon (IFN) signature in SLE is well established, distinguishing lupus patients from healthy controls. Additionally, within lupus patients, higher levels of IFN-responsive gene…
  • Abstract Number: 2026 • 2019 ACR/ARP Annual Meeting

    MicroRNA-27a Can Contribute to Interferon Signatures in Systemic Lupus Erythematosus via the Suppression of Tripartite Motif-containing Protein 27

    Daiga Kishimoto1, Ryusuke Yoshimi 1, Yosuke Kunishita 1, Yumiko Sugiyama 2, Takaaki Komiya 1, Natsuki Sakurai 3, Reikou Kamiyama 1, Yohei Kirino 4 and Hideaki Nakajima 4, 1Department of Stem Cell and Immune Regulation / Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Department of Rheumatic Diseases / Yokohama City University Medical Center, Yokohama, Japan, 3Department of Stem Cell and Immune Regulation / Yokohama City University Graduate School of Medicine, Yokohama City, Japan, 4Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    Background/Purpose: Type Ⅰ interferons (IFN) contribute to antiviral innate immune responses. Upon viral infection, pattern recognition receptors trigger TANK-binding kinase 1 (TBK1) activation and lead…
  • Abstract Number: 2032 • 2019 ACR/ARP Annual Meeting

    Enhanced IFN a Production and STING Pathway in Monocytes in Systemic Lupus Erythematosus Is Suppressed by the Inhibition of mTOR Activation

    Goh Murayama1, Asako Chiba 2, Ayako Makiyama 3, Taiga Kuga 4, Ken Yamaji 4, Naoto Tamura 4 and Sachiko Miyake 2, 1Department of Internal Medicine and Rhumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan, 3Juntendo University School of Medicine, Tokyo, Japan, 4Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan

    Background/Purpose: Interferona (IFNa) is increased and plays an important role in the pathogenesis of systemic lupus erythematosus (SLE). Overexpression of type I IFN regulated genes…
  • Abstract Number: 2033 • 2019 ACR/ARP Annual Meeting

    IRAK4 Inhibition Suppresses TLR7, TLR9, and SLE Serum-Induced IFNA Production in Primary Human Plasmacytoid Dendritic Cells

    Angie Hammond1, Sean Parghi 1, Nathan Wright 1, Ethan Grant 1, James Taylor 1 and Matthew Warr 1, 1Gilead Sciences, Inc., Foster City, CA

    Background/Purpose: A hallmark of lupus is the presence of antinuclear autoantibodies, including those against RNA-protein complexes and double-stranded DNA (dsDNA).1,2 FcγR-mediated internalization of these nucleic…
  • Abstract Number: 2563 • 2019 ACR/ARP Annual Meeting

    PK/PD, Safety and Exploratory Efficacy of Subcutaneous Anifrolumab in SLE: A Phase-II Study in Interferon Type I High Patients with Active Skin Disease

    Ian Bruce1, Alireza Nami 2, Erik Schwetje 3, M Edward Pierson 4, Yen Lin Chia 5, Denison Kuruvilla 5, Gabriel Abreu 6, Raj Tummala 3 and Catharina Lindholm 6, 1University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, 2Joint & Muscle Medical Care, Charlotte, NC, US, Charlotte, NC, 3AstraZeneca, Gaithersburg, MD, USA, Gaithersburg, MD, 4AstraZeneca, Gaithersburg, MD, US, Gaithersburg, MD, 5AstraZeneca, South San Francisco, CA, US, South San Francisco, CA, 6AstraZeneca, Gothenburg, Sweden, Gothenburg, Sweden

    Background/Purpose: Anifrolumab, a fully human anti–IFN Type I receptor mAb, is under investigation for the treatment of SLE at a dose of 300 mg intravenously…
  • Abstract Number: 2280 • 2018 ACR/ARHP Annual Meeting

    Transcriptomic Analysis of Hidradenitis Suppurativa Skin Demonstrates Dysregulation of Antimicrobial Proteins and Inflammatory Pathways

    Victoria Shanmugam1, Derek Jones2, Matthew Bendall3 and Keith Crandall4, 1Rheumatology, The George Washington University, Washington, DC, 2The George Washington University, Washington, DC, 3Department of Microbiology, Immunology and Tropical Medicine, The George Washington University, Washington, DC, 4Department of Biology, The George Washington University, Washington, DC

    Background/Purpose: Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory disease of the apocrine sweat glands. The purpose of the current study was to identify transcripts…
  • Abstract Number: 52 • 2018 ACR/ARHP Annual Meeting

    Interferon-Alpha Protects Against Pain and Joint Damages in Experimental Arthritis and Is Associated with Expansion of Highly Suppressive Regulatory T Lymphocytes in Protected Mice and in Tocilizumab-Treated Rheumatoid Arthritis Patients

    Matthieu Ribon1, Roxane Hervé2, Delphine Lemeiter2, Katarzyna Matyja1, François Santinon1, Darragh Duffy3, Ken Tsumiyama4, Shunichi Shiozawa5, Marie-Christophe Boissier6, Natacha Bessis2 and Patrice Decker1, 1Inserm UMR 1125, Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, 2Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, 3Institut Pasteur, Paris, Paris, France, 4Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan, 5Institute for Rheumatic Diseases, Nagahama, Japan, 6Rheumatology Department, AP-HP, Avicenne Hospital, Bobigny, France

    Background/Purpose: Type I interferons (IFN-I) can be both anti- and pro-inflammatory. Among them, IFN-α inhibits normal Th17 differentiation, whereas it is pathogenic in lupus. The…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology